Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-18
DOI
10.1038/s41409-018-0364-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease
- (2018) Alexander Coltoff et al. BONE MARROW TRANSPLANTATION
- Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases
- (2018) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials
- (2016) Armin Rashidi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
- (2016) Tim Wyant et al. Journal of Crohns & Colitis
- Localization of dendritic cells in the gut epithelium requires MAdCAM-1
- (2015) Thomas Clahsen et al. CLINICAL IMMUNOLOGY
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
- (2014) Tim Wyant et al. GUT
- Prognosis of grade 3–4 acute GVHD continues to be dismal
- (2013) K Jamani et al. BONE MARROW TRANSPLANTATION
- Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice
- (2013) T Ruutu et al. BONE MARROW TRANSPLANTATION
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review
- (2012) Paul J. Martin et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
- (2012) Paul J. Martin et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Expression of α4β7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD
- (2012) Y-B Chen et al. BONE MARROW TRANSPLANTATION
- Diagnosis and management of acute graft-versus-host disease
- (2012) Fiona L. Dignan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment
- (2011) Aliénor Xhaard et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Glucocorticoid-Refractory Acute Graft-versus-Host Disease
- (2010) Joseph Pidala et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Nonabsorbable Corticosteroids Use in the Treatment of Gastrointestinal Graft-versus-Host Disease
- (2009) Rami B. Ibrahim et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started